Long-Acting Drug Delivery Market: By Type (First Generation, Second Generation), By Route of administration (Parenteral, Injectables, Oral, Others), By Application (Ophthalmic Disorders, Oncological Disorders, Neurological Disorders, Infectious Diseases) and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Long-Acting Drug Delivery Market size was valued at USD 1.08 billion in 2023 and is poised to grow at a CAGR of 12.2% form 2024-2030. Long-acting drug delivery is a novel drug delivery method that allows a medicine to remain active in the patient's body for weeks, months, or years following a single dosage while maintaining its ideal therapeutic level. Given the trend toward cutting-edge long-acting technologies, as well as creative approaches to tailoring dosing regimens, we predict that the evolution of technologies and services for the long-acting medicines market will accelerate throughout the projected period.

Long Acting Drug Delivery Market Key Developments:
  • In May 2023, Lyndra Therapeutics published findings on long-acting oral weekly Risperidone (LYN-005) at the American Society of Clinical Psychopharmacology 2023 Annual Conference.
  • In May 2023, The FDA approved Uzedy™ (risperidone extended-release injectable suspension) to treat adults with schizophrenia.
  • In April 2023, The U.S. FDA has approved ABILIFY ASIMTUFII®, a long-acting injectable suspension taken intramuscularly once every two months for the treatment of schizophrenia or as a maintenance monotherapy for biopolar I disorder in adults. Otsuka and Lundbeck collaborated in its development.

Long Acting Drug Delivery Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

12.2%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Long-Acting Drug Delivery Market Dynamics

Long-acting administration of drug candidates provides various benefits, including enhanced patient compliance, lower dosage requirements, better medicine adherence, reduced failure risk due to inconsistent usage, and increased patient convenience. It is noteworthy that a suitable combination of dosage form (long-acting implants, injectables, vaginal, oral, and topical / transdermal dosage forms) and strategy (micro-encapsulation, nanocrystal suspensions, long-acting hydrogels, and microneedles) allows for better bio-distribution and localized therapeutic action of the drug for an extended period. The long-acting drug delivery market is expected to increase significantly in the coming years, owing to the constant rate of innovation in the formulation of these technologies and the rising need for long-acting pharmaceuticals. Furthermore, the formulation of these medications is a complicated procedure, particularly when highly potent compounds are included. Other problems include aseptic manufacture, terminal sterilization, appropriate characterisation methods, a shortage of GMP-certified facilities, and specialized equipment. Furthermore, scale-up and regulatory filing for a less-defined regulatory pathway frequently serve as bottlenecks in the clinical and commercial translation of these medications.

Long Acting Drug Delivery Market Segmentation

By Type

  • First Generation
  • Second Generation

By Route of Administration

  • Parenteral
  • Injectables
  • Oral
  • Others

By Application

  • Ophthalmic Disorders
  • Oncological Disorders
  • Neurological Disorders
  • Infectious Diseases

Frequently Asked Questions

The Long-Acting Drug Delivery Market is Projected to grow at a CAGR of 12.2% over 2025-2030.

The desire for greater patient convenience and compliance, medication adherence, and lower dosage requirements for the treatment of a variety of diseases, particularly chronic diseases, has increased demand for long-acting drug delivery formulations.

Recent trend toward cutting-edge long-acting technology, as well as innovative approaches to tailoring the dosing regimen, therefore the market is expected to grow rapidly during the projected period.

Market research is segmented based on type, route of administration, application, and region.

North America and Europe is estimated to have highest share with the highest CAGR over the forecast period.

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Long Acting Drug Delivery Market Introduction 
2.1.Global Long Acting Drug Delivery Market  - Taxonomy
2.2.Global Long Acting Drug Delivery Market  - Definitions
2.2.1.Type 
2.2.2.Application
2.2.3.Route of Administration 
2.2.4.Region
3.Global Long Acting Drug Delivery Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Long Acting Drug Delivery Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Long Acting Drug Delivery Market  By Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. First Generation
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Second Generation
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Long Acting Drug Delivery Market  By Application, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Ophthalmic Disorders
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Oncological Disorders
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Neurological Disorders
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Infectious Diseases
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7.Global Long Acting Drug Delivery Market  By Route of Administration , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Parenteral
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Injectables
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Oral
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Others
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8.Global Long Acting Drug Delivery Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Long Acting Drug Delivery Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.First Generation
9.1.2.Second Generation
9.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Ophthalmic Disorders
9.2.2.Oncological Disorders
9.2.3.Neurological Disorders
9.2.4.Infectious Diseases
9.3.  Route of Administration  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Parenteral
9.3.2.Injectables
9.3.3.Oral
9.3.4.Others
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Long Acting Drug Delivery Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.First Generation
10.1.2.Second Generation
10.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Ophthalmic Disorders
10.2.2.Oncological Disorders
10.2.3.Neurological Disorders
10.2.4.Infectious Diseases
10.3.  Route of Administration  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Parenteral
10.3.2.Injectables
10.3.3.Oral
10.3.4.Others
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Long Acting Drug Delivery Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.First Generation
11.1.2.Second Generation
11.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Ophthalmic Disorders
11.2.2.Oncological Disorders
11.2.3.Neurological Disorders
11.2.4.Infectious Diseases
11.3.  Route of Administration  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Parenteral
11.3.2.Injectables
11.3.3.Oral
11.3.4.Others
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Long Acting Drug Delivery Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.First Generation
12.1.2.Second Generation
12.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Ophthalmic Disorders
12.2.2.Oncological Disorders
12.2.3.Neurological Disorders
12.2.4.Infectious Diseases
12.3.  Route of Administration  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Parenteral
12.3.2.Injectables
12.3.3.Oral
12.3.4.Others
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Long Acting Drug Delivery Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.First Generation
13.1.2.Second Generation
13.2.  Application Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Ophthalmic Disorders
13.2.2.Oncological Disorders
13.2.3.Neurological Disorders
13.2.4.Infectious Diseases
13.3.  Route of Administration  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Parenteral
13.3.2.Injectables
13.3.3.Oral
13.3.4.Others
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Eli Lilly and Company
14.2.2.Janssen Pharmaceutical
14.2.3.Cipla
14.2.4.GSK Plc
14.2.5.Alnylam Pharmaceuticals
14.2.6.Heron Therapeutics
14.2.7.Nanexa AB
14.2.8.Amorphex Therapeutics
14.2.9.AstraZeneca
14.2.10.Bostal Drug Delivery Co., Ltd
15. Research Methodology 
16. Appendix and Abbreviations 
  • Eli Lilly and Company
  • Janssen Pharmaceutical
  • Cipla
  • GSK Plc
  • Alnylam Pharmaceuticals
  • Heron Therapeutics
  • Nanexa AB
  • Amorphex Therapeutics
  • AstraZeneca
  • Bostal Drug Delivery Co., Ltd

Adjacent Markets